Differential expression and tumorigenic function of neurotensin receptor 1 in neuroendocrine tumor cells

Ji Tae Kim, Jing Li, Jun Song, Eun Y. Lee, Heidi L. Weiss, Courtney Townsend, B. Mark Evers

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Neurotensin (NTS), localized predominantly to the small bowel, stimulates the growth of a variety of cancers, including neuroendocrine tumors (NETs), mainly through its interaction with the high-affinity NTS receptor 1 (NTSR1). Here, we observed increased expression of NTSR1 in almost all tested clinical NET samples, but not in normal tissues. Through RT-PCR analysis, we found that the expression of NTSR1 and NTSR2 was either variable (NTSR1) or absent (NTSR2) in human NET cell lines. In contrast, NTSR3 and NTS were expressed in all NET cells. Treatment with 5-aza-2'-deoxycytidine, a demethylating agent, increased levels of NTSR1 and NTSR2 suggesting that DNA methylation contributes to NTSR1/2 expression patterns, which was confirmed by methylation analyses. In addition, we found that knockdown of NTSR1 decreased proliferation, expression levels of growth-related proteins, and anchorage-independent growth of BON human carcinoid cells. Moreover, stable silencing of NTSR1 suppressed BON cell growth, adhesion, migration and invasion. Our results show that high expression of NTSR1 is found in clinical NETs and that promoter methylation is an important mechanism controlling the differential expression of NTSR1 and silencing of NTSR2 in NET cells. Furthermore, knockdown of NTSR1 in BON cells suppressed oncogenic functions suggesting that NTSR1 contributes to NET tumorigenesis.

Original languageEnglish (US)
Pages (from-to)26960-26970
Number of pages11
JournalOncotarget
Volume6
Issue number29
DOIs
StatePublished - 2015

Fingerprint

Neuroendocrine Cells
Neuroendocrine Tumors
Neurotensin
decitabine
Growth
Methylation
Carcinoid Tumor
DNA Methylation
neurotensin type 1 receptor
Tumor Cell Line
Cell Adhesion
Carcinogens
Carcinogenesis
Polymerase Chain Reaction

Keywords

  • Cell growth
  • Cell migration
  • Neuroendocrine tumor
  • Neurotensin receptor 1
  • Promoter methylation

ASJC Scopus subject areas

  • Oncology

Cite this

Differential expression and tumorigenic function of neurotensin receptor 1 in neuroendocrine tumor cells. / Kim, Ji Tae; Li, Jing; Song, Jun; Lee, Eun Y.; Weiss, Heidi L.; Townsend, Courtney; Evers, B. Mark.

In: Oncotarget, Vol. 6, No. 29, 2015, p. 26960-26970.

Research output: Contribution to journalArticle

Kim, Ji Tae ; Li, Jing ; Song, Jun ; Lee, Eun Y. ; Weiss, Heidi L. ; Townsend, Courtney ; Evers, B. Mark. / Differential expression and tumorigenic function of neurotensin receptor 1 in neuroendocrine tumor cells. In: Oncotarget. 2015 ; Vol. 6, No. 29. pp. 26960-26970.
@article{950b716971b34d11aa0e9be1554ba6a3,
title = "Differential expression and tumorigenic function of neurotensin receptor 1 in neuroendocrine tumor cells",
abstract = "Neurotensin (NTS), localized predominantly to the small bowel, stimulates the growth of a variety of cancers, including neuroendocrine tumors (NETs), mainly through its interaction with the high-affinity NTS receptor 1 (NTSR1). Here, we observed increased expression of NTSR1 in almost all tested clinical NET samples, but not in normal tissues. Through RT-PCR analysis, we found that the expression of NTSR1 and NTSR2 was either variable (NTSR1) or absent (NTSR2) in human NET cell lines. In contrast, NTSR3 and NTS were expressed in all NET cells. Treatment with 5-aza-2'-deoxycytidine, a demethylating agent, increased levels of NTSR1 and NTSR2 suggesting that DNA methylation contributes to NTSR1/2 expression patterns, which was confirmed by methylation analyses. In addition, we found that knockdown of NTSR1 decreased proliferation, expression levels of growth-related proteins, and anchorage-independent growth of BON human carcinoid cells. Moreover, stable silencing of NTSR1 suppressed BON cell growth, adhesion, migration and invasion. Our results show that high expression of NTSR1 is found in clinical NETs and that promoter methylation is an important mechanism controlling the differential expression of NTSR1 and silencing of NTSR2 in NET cells. Furthermore, knockdown of NTSR1 in BON cells suppressed oncogenic functions suggesting that NTSR1 contributes to NET tumorigenesis.",
keywords = "Cell growth, Cell migration, Neuroendocrine tumor, Neurotensin receptor 1, Promoter methylation",
author = "Kim, {Ji Tae} and Jing Li and Jun Song and Lee, {Eun Y.} and Weiss, {Heidi L.} and Courtney Townsend and Evers, {B. Mark}",
year = "2015",
doi = "10.18632/oncotarget.4745",
language = "English (US)",
volume = "6",
pages = "26960--26970",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "29",

}

TY - JOUR

T1 - Differential expression and tumorigenic function of neurotensin receptor 1 in neuroendocrine tumor cells

AU - Kim, Ji Tae

AU - Li, Jing

AU - Song, Jun

AU - Lee, Eun Y.

AU - Weiss, Heidi L.

AU - Townsend, Courtney

AU - Evers, B. Mark

PY - 2015

Y1 - 2015

N2 - Neurotensin (NTS), localized predominantly to the small bowel, stimulates the growth of a variety of cancers, including neuroendocrine tumors (NETs), mainly through its interaction with the high-affinity NTS receptor 1 (NTSR1). Here, we observed increased expression of NTSR1 in almost all tested clinical NET samples, but not in normal tissues. Through RT-PCR analysis, we found that the expression of NTSR1 and NTSR2 was either variable (NTSR1) or absent (NTSR2) in human NET cell lines. In contrast, NTSR3 and NTS were expressed in all NET cells. Treatment with 5-aza-2'-deoxycytidine, a demethylating agent, increased levels of NTSR1 and NTSR2 suggesting that DNA methylation contributes to NTSR1/2 expression patterns, which was confirmed by methylation analyses. In addition, we found that knockdown of NTSR1 decreased proliferation, expression levels of growth-related proteins, and anchorage-independent growth of BON human carcinoid cells. Moreover, stable silencing of NTSR1 suppressed BON cell growth, adhesion, migration and invasion. Our results show that high expression of NTSR1 is found in clinical NETs and that promoter methylation is an important mechanism controlling the differential expression of NTSR1 and silencing of NTSR2 in NET cells. Furthermore, knockdown of NTSR1 in BON cells suppressed oncogenic functions suggesting that NTSR1 contributes to NET tumorigenesis.

AB - Neurotensin (NTS), localized predominantly to the small bowel, stimulates the growth of a variety of cancers, including neuroendocrine tumors (NETs), mainly through its interaction with the high-affinity NTS receptor 1 (NTSR1). Here, we observed increased expression of NTSR1 in almost all tested clinical NET samples, but not in normal tissues. Through RT-PCR analysis, we found that the expression of NTSR1 and NTSR2 was either variable (NTSR1) or absent (NTSR2) in human NET cell lines. In contrast, NTSR3 and NTS were expressed in all NET cells. Treatment with 5-aza-2'-deoxycytidine, a demethylating agent, increased levels of NTSR1 and NTSR2 suggesting that DNA methylation contributes to NTSR1/2 expression patterns, which was confirmed by methylation analyses. In addition, we found that knockdown of NTSR1 decreased proliferation, expression levels of growth-related proteins, and anchorage-independent growth of BON human carcinoid cells. Moreover, stable silencing of NTSR1 suppressed BON cell growth, adhesion, migration and invasion. Our results show that high expression of NTSR1 is found in clinical NETs and that promoter methylation is an important mechanism controlling the differential expression of NTSR1 and silencing of NTSR2 in NET cells. Furthermore, knockdown of NTSR1 in BON cells suppressed oncogenic functions suggesting that NTSR1 contributes to NET tumorigenesis.

KW - Cell growth

KW - Cell migration

KW - Neuroendocrine tumor

KW - Neurotensin receptor 1

KW - Promoter methylation

UR - http://www.scopus.com/inward/record.url?scp=84944463324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944463324&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.4745

DO - 10.18632/oncotarget.4745

M3 - Article

VL - 6

SP - 26960

EP - 26970

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 29

ER -